{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:55:26Z","timestamp":1791608126232,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical and Health Science and Technology Planning Project of Zhejiang Province","award":["2021455749"],"award-info":[{"award-number":["2021455749"]}]},{"name":"Zhejiang Natural Science Foundation of China","award":["LBZ22H160001"],"award-info":[{"award-number":["LBZ22H160001"]}]},{"name":"Health Science and Technology Projects of Hangzhou","award":["A20220441"],"award-info":[{"award-number":["A20220441"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acral melanoma (AM) is a subtype of melanoma with high prevalence in East Asians. AM is characterized by greater aggressiveness and lower survival rates. However, there are still fewer studies on immune mechanisms of AM especially subungual melanoma (SM) versus non-subungual melanoma (NSM). In order to explore tumor heterogeneity and immune microenvironment in different subtypes of AM, we applied single-cell RNA sequencing to 24,789 single cells isolated from the SM and plantar melanoma (PM) patients. Aspects of tumor heterogeneity, melanocytes from PM and SM had significant differences in gene expression, CNV and pathways in which tumor-associated such as NF-kb and Wnt were involved. Regarding the immune microenvironment, PM contained more fibroblasts and T\/NK cells. The EPHA3-EFNA1 axis was expressed only in cancer-associated fibroblast (CAF) and melanocytes of PM, and the TIGIT-NECTIN2 axis was expressed in both AM subtypes of T\/NK cells and melanocytes. Altogether, our study helps to elucidate the tumor heterogeneity in AM subpopulations and provides potential therapeutic targets for clinical research.<\/jats:p>","DOI":"10.1038\/s41598-024-57640-8","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:02:24Z","timestamp":1711371744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Single-cell RNA sequencing unveils tumor heterogeneity and immune microenvironment between subungual and plantar melanoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Panpan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yige","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"57640_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007567","author":"RC Augustin","year":"2023","unstructured":"Augustin, R. C. et al. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2023-007567 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"57640_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.06.056","author":"L Si","year":"2012","unstructured":"Si, L. et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur. J. Cancer https:\/\/doi.org\/10.1016\/j.ejca.2011.06.056 (2012).","journal-title":"Eur. J. Cancer"},{"key":"57640_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ejca.2021.02.021","volume":"148","author":"L Mao","year":"2021","unstructured":"Mao, L. et al. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur. J. Cancer 148, 297\u2013306. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.021 (2021).","journal-title":"Eur. J. Cancer"},{"key":"57640_CR4","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","volume":"31","author":"FS Hodi","year":"2013","unstructured":"Hodi, F. S. et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol. 31, 3182\u20133190. https:\/\/doi.org\/10.1200\/JCO.2012.47.7836 (2013).","journal-title":"J. Clin. Oncol."},{"key":"57640_CR5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","volume":"31","author":"Y Nakamura","year":"2020","unstructured":"Nakamura, Y. et al. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: A multicenter study of 193 Japanese patients. Ann. Oncol. 31, 1198\u20131206. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.031 (2020).","journal-title":"Ann. Oncol."},{"key":"57640_CR6","doi-asserted-by":"publisher","first-page":"e0219829","DOI":"10.1371\/journal.pone.0219829","volume":"14","author":"J Guo","year":"2019","unstructured":"Guo, J. et al. Empowering therapeutic antibodies with IFN-\u03b1 for cancer immunotherapy. PLoS ONE 14, e0219829. https:\/\/doi.org\/10.1371\/journal.pone.0219829 (2019).","journal-title":"PLoS ONE"},{"key":"57640_CR7","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","volume":"11","author":"F Newell","year":"2020","unstructured":"Newell, F. et al. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat. Commun. 11, 5259. https:\/\/doi.org\/10.1038\/s41467-020-18988-3 (2020).","journal-title":"Nat. Commun."},{"key":"57640_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/CMR.0000000000000688","volume":"30","author":"BN Holman","year":"2020","unstructured":"Holman, B. N. et al. Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. Melanoma Res. 30, 562\u2013573. https:\/\/doi.org\/10.1097\/CMR.0000000000000688 (2020).","journal-title":"Melanoma Res."},{"key":"57640_CR9","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside, T. L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904\u20135912. https:\/\/doi.org\/10.1038\/onc.2008.271 (2008).","journal-title":"Oncogene"},{"key":"57640_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9060054","author":"M Schoepp","year":"2017","unstructured":"Schoepp, M., Str\u00f6se, A. J. & Haier, J. Dysregulation of miRNA expression in cancer associated fibroblasts (CAFs) and its consequences on the tumor microenvironment. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers9060054 (2017).","journal-title":"Cancers (Basel)"},{"key":"57640_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.coi.2013.03.004","volume":"25","author":"H Angell","year":"2013","unstructured":"Angell, H. & Galon, J. From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 25, 261\u2013267. https:\/\/doi.org\/10.1016\/j.coi.2013.03.004 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"57640_CR12","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1038\/s41467-023-40755-3","volume":"14","author":"JD Worboys","year":"2023","unstructured":"Worboys, J. D. et al. TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation. Nat. Commun. 14, 5016. https:\/\/doi.org\/10.1038\/s41467-023-40755-3 (2023).","journal-title":"Nat. Commun."},{"key":"57640_CR13","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.immuni.2020.09.006","volume":"53","author":"M Weulersse","year":"2020","unstructured":"Weulersse, M. et al. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8+ T cell anti-tumor functions and limits the efficacy of cancer immunotherapy. Immunity 53, 824\u2013839. https:\/\/doi.org\/10.1016\/j.immuni.2020.09.006 (2020).","journal-title":"Immunity"},{"key":"57640_CR14","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1158\/1078-0432.CCR-13-0259","volume":"19","author":"KE Sheppard","year":"2013","unstructured":"Sheppard, K. E. & McArthur, G. A. The cell-cycle regulator CDK4: An emerging therapeutic target in melanoma. Clin. Cancer Res. 19, 5320\u20135328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0259 (2013).","journal-title":"Clin. Cancer Res."},{"key":"57640_CR15","doi-asserted-by":"publisher","first-page":"6946","DOI":"10.1158\/1078-0432.CCR-17-0070","volume":"23","author":"Y Kong","year":"2017","unstructured":"Kong, Y. et al. Frequent genetic aberrations in the CDK4 Pathway in acral melanoma indicate the potential for CDK4\/6 inhibitors in targeted therapy. Clin. Cancer Res. 23, 6946\u20136957. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0070 (2017).","journal-title":"Clin. Cancer Res."},{"key":"57640_CR16","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2817876\/v1","author":"V Rebecca","year":"2023","unstructured":"Rebecca, V. et al. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4\/6 inhibitor resistance in acral lentiginous melanoma. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-2817876\/v1 (2023).","journal-title":"Res. Sq."},{"key":"57640_CR17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jid.2021.09.010","volume":"142","author":"L Van Hove","year":"2022","unstructured":"Van Hove, L. & Hoste, E. Activation of fibroblasts in skin cancer. J. Invest. Dermatol. 142, 1026\u20131031. https:\/\/doi.org\/10.1016\/j.jid.2021.09.010 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"57640_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13046-023-02747-5","volume":"42","author":"M Talia","year":"2023","unstructured":"Talia, M. et al. The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells. J. Exp. Clin. Cancer Res. 42, 164. https:\/\/doi.org\/10.1186\/s13046-023-02747-5 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"57640_CR19","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.3390\/cancers15184646","volume":"15","author":"ME Vail","year":"2023","unstructured":"Vail, M. E. et al. Inhibition of EphA3 expression in tumour stromal cells suppresses tumour growth and progression. Cancers (Basel) 15, 4646. https:\/\/doi.org\/10.3390\/cancers15184646 (2023).","journal-title":"Cancers (Basel)"},{"key":"57640_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/onc.2013.590","volume":"34","author":"H Miao","year":"2015","unstructured":"Miao, H. et al. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene 34, 558\u2013567. https:\/\/doi.org\/10.1038\/onc.2013.590 (2015).","journal-title":"Oncogene"},{"key":"57640_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1349-7006.2005.00007.x","volume":"96","author":"R Nakamura","year":"2005","unstructured":"Nakamura, R. et al. EPHA2\/EFNA1 expression in human gastric cancer. Cancer Sci. 96, 42\u201347 (2005).","journal-title":"Cancer Sci."},{"key":"57640_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1755-8794-5-52","volume":"5","author":"Z-Z Shi","year":"2012","unstructured":"Shi, Z.-Z. et al. Genomic profiling of rectal adenoma and carcinoma by array-based comparative genomic hybridization. BMC Med. Genom. 5, 52. https:\/\/doi.org\/10.1186\/1755-8794-5-52 (2012).","journal-title":"BMC Med. Genom."},{"key":"57640_CR23","doi-asserted-by":"publisher","first-page":"e102262","DOI":"10.1371\/journal.pone.0102262","volume":"9","author":"MI Toma","year":"2014","unstructured":"Toma, M. I. et al. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma. PLoS ONE 9, e102262. https:\/\/doi.org\/10.1371\/journal.pone.0102262 (2014).","journal-title":"PLoS ONE"},{"key":"57640_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1472-6890-13-19","volume":"13","author":"K Miyazaki","year":"2013","unstructured":"Miyazaki, K. et al. EphA4 is a prognostic factor in gastric cancer. BMC Clin. Pathol. 13, 19. https:\/\/doi.org\/10.1186\/1472-6890-13-19 (2013).","journal-title":"BMC Clin. Pathol."},{"key":"57640_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","volume":"14","author":"W Tang","year":"2023","unstructured":"Tang, W., Chen, J., Ji, T. & Cong, X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis. 14, 466. https:\/\/doi.org\/10.1038\/s41419-023-05961-3 (2023).","journal-title":"Cell Death Dis."},{"key":"57640_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41389-021-00355-6","volume":"10","author":"K Xu","year":"2021","unstructured":"Xu, K. et al. Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis. Oncogenesis 10, 66. https:\/\/doi.org\/10.1038\/s41389-021-00355-6 (2021).","journal-title":"Oncogenesis"},{"key":"57640_CR27","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1038\/s41467-021-25865-0","volume":"12","author":"K Takamatsu","year":"2021","unstructured":"Takamatsu, K. et al. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. Nat. Commun 12, 5547. https:\/\/doi.org\/10.1038\/s41467-021-25865-0 (2021).","journal-title":"Nat. Commun"},{"key":"57640_CR28","doi-asserted-by":"publisher","first-page":"106198","DOI":"10.1016\/j.intimp.2020.106198","volume":"80","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma). Int. Immunopharmacol. 80, 106198. https:\/\/doi.org\/10.1016\/j.intimp.2020.106198 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"57640_CR29","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00262-019-02426-5","volume":"68","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. Cancer Immunol. Immunother. 68, 2041\u20132054. https:\/\/doi.org\/10.1007\/s00262-019-02426-5 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"57640_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/CBM-210159","volume":"33","author":"J Ma","year":"2022","unstructured":"Ma, J. Bioinformatics-guided analysis uncovers TIGIT as an epigenetically regulated immunomodulator affecting immunotherapeutic sensitivity of gastric cancer. Cancer Biomark. 33, 349\u2013358. https:\/\/doi.org\/10.3233\/CBM-210159 (2022).","journal-title":"Cancer Biomark."},{"key":"57640_CR31","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-20-0558","volume":"26","author":"Z-Z Yang","year":"2020","unstructured":"Yang, Z.-Z. et al. TIGIT expression is associated with t-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma. Clin. Cancer Res. 26, 5217\u20135231. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0558 (2020).","journal-title":"Clin. Cancer Res."},{"key":"57640_CR32","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1158\/1078-0432.CCR-20-2725","volume":"27","author":"T Shaffer","year":"2021","unstructured":"Shaffer, T., Natarajan, A. & Gambhir, S. S. PET imaging of TIGIT expression on tumor-infiltrating lymphocytes. Clin. Cancer Res. 27, 1932\u20131940. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2725 (2021).","journal-title":"Clin. Cancer Res."},{"key":"57640_CR33","doi-asserted-by":"publisher","first-page":"602555","DOI":"10.3389\/fonc.2020.602555","volume":"10","author":"J-A Zhang","year":"2020","unstructured":"Zhang, J.-A. et al. Development of an immune-related gene signature for prognosis in melanoma. Front. Oncol. 10, 602555. https:\/\/doi.org\/10.3389\/fonc.2020.602555 (2020).","journal-title":"Front. Oncol."},{"key":"57640_CR34","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1245\/s10434-020-09277-w","volume":"28","author":"NE Farrow","year":"2021","unstructured":"Farrow, N. E. et al. Characterization of sentinel lymph node immune signatures and implications for risk stratification for adjuvant therapy in melanoma. Ann. Surg. Oncol. 28, 3501\u20133510. https:\/\/doi.org\/10.1245\/s10434-020-09277-w (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"57640_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/JID.2015.404","volume":"136","author":"T Inozume","year":"2016","unstructured":"Inozume, T. et al. Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase. J. Invest. Dermatol. 136, 255\u2013263. https:\/\/doi.org\/10.1038\/JID.2015.404 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"57640_CR36","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.4049\/jimmunol.1003081","volume":"186","author":"N Joller","year":"2011","unstructured":"Joller, N. et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J. Immunol. 186, 1338\u20131342. https:\/\/doi.org\/10.4049\/jimmunol.1003081 (2011).","journal-title":"J. Immunol."},{"key":"57640_CR37","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/cdd.2012.141","volume":"20","author":"S Liu","year":"2013","unstructured":"Liu, S. et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ. 20, 456\u2013464. https:\/\/doi.org\/10.1038\/cdd.2012.141 (2013).","journal-title":"Cell Death Differ."},{"key":"57640_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","volume":"40","author":"N Joller","year":"2014","unstructured":"Joller, N. et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40, 569\u2013581. https:\/\/doi.org\/10.1016\/j.immuni.2014.02.012 (2014).","journal-title":"Immunity"},{"key":"57640_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121157","author":"J Fourcade","year":"2018","unstructured":"Fourcade, J. et al. CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.121157 (2018).","journal-title":"JCI Insight"},{"key":"57640_CR40","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","volume":"188","author":"E Lozano","year":"2012","unstructured":"Lozano, E., Dominguez-Villar, M., Kuchroo, V. & Hafler, D. A. The TIGIT\/CD226 axis regulates human T cell function. J. Immunol. 188, 3869\u20133875. https:\/\/doi.org\/10.4049\/jimmunol.1103627 (2012).","journal-title":"J. Immunol."},{"key":"57640_CR41","doi-asserted-by":"publisher","first-page":"E11731","DOI":"10.1073\/pnas.1814052115","volume":"115","author":"X Du","year":"2018","unstructured":"Du, X. et al. CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1. Proc. Natl. Acad. Sci. U. S. A. 115, E11731\u2013E11740. https:\/\/doi.org\/10.1073\/pnas.1814052115 (2018).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"57640_CR42","doi-asserted-by":"publisher","first-page":"2217735","DOI":"10.1080\/2162402X.2023.2217735","volume":"12","author":"A Rishiq","year":"2023","unstructured":"Rishiq, A., Bsoul, R., Pick, O. & Mandelboim, O. Studying TIGIT activity against tumors through the generation of knockout mice. Oncoimmunology 12, 2217735. https:\/\/doi.org\/10.1080\/2162402X.2023.2217735 (2023).","journal-title":"Oncoimmunology"},{"key":"57640_CR43","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-21-3145","volume":"28","author":"J Li","year":"2022","unstructured":"Li, J. et al. Single-cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy. Clin. Cancer Res. 28, 2131\u20132146. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3145 (2022).","journal-title":"Clin. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57640-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57640-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57640-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:04:11Z","timestamp":1711371851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57640-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["57640"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-57640-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7039"}}